FOLLICULAR LYMPHOMA (FL)

This early-stage study tests a new drug called NX-2127 in adults with certain blood cancers (like CLL or lymphoma) that have returned or not improved after other treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. About …

This study tests an experimental drug called NX-5948 in adults with certain blood cancers (like CLL or lymphoma) that have come back or stopped responding to treatment. The drug works by breaking down a protein that helps cancer cells grow. The main goals are to find a safe dose …

This early-phase study tests a new drug called LTZ-301 in 42 adults with certain types of non-Hodgkin lymphoma that have not responded to at least two prior treatments. The main goal is to check the drug's safety and find the right dose. Researchers will also look for signs that …

This study tests a new treatment called Talikabtagene autoleucel (a CAR-T cell therapy) for adults with B-cell cancers like leukemia or lymphoma that have come back or not responded to standard treatments. The therapy uses a patient's own immune cells, modified to target cancer c…

This early-stage study tests an experimental drug called mevrometostat in adults with advanced prostate cancer, small cell lung cancer, or follicular lymphoma that has stopped responding to standard treatments. The main goals are to find a safe dose and see if the drug can shrink…

This early-phase study tests a new cell therapy called GF-CART01 in 18 adults aged 18-70 with B-cell blood cancers (like lymphoma) that have come back or not responded to standard treatments. The therapy uses a patient's own immune cells, modified to target two markers (CD20 and …

This study tests whether adding the experimental drug epcoritamab to standard treatments (rituximab and lenalidomide) works better than standard chemo for people with untreated follicular lymphoma, a slow-growing blood cancer. About 1095 adults will be randomly assigned to differ…

This study tests a new drug called surovatamig in 240 adults with a type of blood cancer (B-cell non-Hodgkin lymphoma) that has returned or not improved after at least two prior treatments. The drug is given alone to see if it can shrink tumors and how safe it is. The trial is op…

This study tests an experimental drug called MDX2003 in about 180 adults with B-cell lymphomas (like diffuse large B-cell lymphoma or follicular lymphoma) that have returned or not improved after at least two prior treatments. The main goals are to find the safest dose and to see…

This early study tests a new treatment called CT1182 for adults with B-cell non-Hodgkin lymphoma that has come back or not responded to other therapies. About 24 participants will receive the treatment to see if it is safe and can shrink tumors. The goal is to find the best dose …

This study tests a new drug, odronextamab, for people with untreated follicular lymphoma, a type of blood cancer. In the first part, researchers check the drug's safety alone. In the second part, they compare it to standard treatments like rituximab plus chemotherapy. About 822 p…

This study tests a combination of two treatments—relmacabtagene autoleucel (a type of cell therapy) and sintilimab (an immunotherapy drug)—in 30 adults with relapsed or refractory B-cell lymphoma (including diffuse large B-cell, mantle cell, and follicular lymphoma). The goal is …

This study is a registry that collects information from about 2,950 adults with certain blood cancers (like CLL, DLBCL, and others) in Germany. Researchers will track what treatments patients receive, how well they work, and how patients feel over time. No new drugs or treatments…

This study is for people with acute myeloid leukemia (AML) or follicular lymphoma. Researchers will collect blood and leftover tissue samples during routine care to look for genetic markers that may predict how the disease progresses or responds to treatment. The goal is to bette…